Arguably the best medical imaging tool in common use today, Magnetic Resonance Imaging (MRI) enables a clinician to “see” in detail the internal organs of a patient non-invasively while thermal coagulation therapy has proven utility in multiple medical treatment applications.

 

When combining the two methodologies, the opportunity exists for an optimal and vastly superior clinical outcome. Profound has developed a novel MRI-compatible ultrasound applicator to deliver controlled thermal therapy to the regions of the prostate gland via a trans-urethral approach. Featuring intelligent closed-loop control via real-time thermal imaging, the Profound system offers unparalleled accuracy.

The system has been extensively tested and delivered consistent and predictable proof-of-concept results in mathematical, gel, pre-clinical models and the technology is approved for Safety and Feasibility Clinical trials in North America and Europe, currently enrolling patients. 

 

System Features 

• Safety & compatibility within an MRI suite
• Accurate location of the trans-urethral ultrasound applicator in the prostate
• Customisable 3D treatment planning options through proprietary software
• Precise heating control through unique array geometries and frequencies
• Whole or segmented treatments relative to disease progression and location
• Single treatment, within MR scanner, on outpatient basis
• Real-time thermometry for active monitoring and surveillance
• Control around critical organs such as nerve bundles, rectum & bladder

Jean-François Pariseau joined BDC Venture Capital in July 2001. He has over 17 years of investment and entrepreneurial experience in the life sciences sector. He has invested and managed more than $200 million in biopharmaceutical and medical device companies in North America. Jean-Francois’ experience includes transactions in private and in public companies, IPOs, M&A and fund investments. Prior to this, he was CEO of a consulting company specializing in regulatory affairs as well as VP, R&D for a pharmaceutical-product distribution company, both of which he founded. Mr. Pariseau holds a Bachelor of Science in Biotechnology from Université de Sherbrooke, a Master of Science in Biomedical Sciences from Université de Montréal, and an MBA from HEC-Montréal. He currently sits on the Board of Directors of AngioChem Inc., Osprey Pharmaceuticals USA, Profound Medical Inc. and BioQuébec.

 

Damian Lamb, Genesys Capital Partners Co-Founder and Managing Director
Mr. Lamb is co-Founder and Managing Director of Genesys Capital. He brings a unique experience base, blending skills in both the commercial and technical side of biotechnology. Since co-founding Genesys Capital in 2000, Mr. Lamb has been instrumental in raising over $200 million in venture capital funds, and has been involved in deploying over $90 million in 18 investments. He currently serves on the Board of Affinium Pharmaceuticals Inc.. He has served on the Board of Ionalytics Corporation (recently sold to Thermo Electron Corp.), Millenium Biologix and was Chairman of the Board of DELEX Therapeutics Inc. when it was sold to YM BioSciences. Mr. Lamb works closely with Genesys investee companies to strategically position the companies to build value for shareholders.

Steven Plymale, CEO, Profound Medical Inc.
Mr. Plymale has over two decades of senior management experience in the medical device industry and was most recently the Vice President and General Manager of Xltek, a division of Natus Medical Incorporated. Xltek, formerly a public company, was acquired by Natus Medical in November 2007, and designs, manufactures and sells a broad portfolio of diagnostic monitoring devices for Neurology. Prior to this appointment Mr. Plymale served in various senior management roles within several medical device companies (such as ISG Technologices,/Cedara Software, CryoCath Technology, Claron Technology and The Bluehaven Consulting group). Mr. Plymale brings a unique blend of management skills and experience focusing on Operations, Quality & Regulatory Affairs and Strategic Planning.

William E. Curran

Mr. Curran has extensive experience in operations, finance and executive management. He was formerly President and Chief Executive Officer of Philips Electronics North America. He served in diverse functional and senior management positions during his career with Philips, including as Chief Operating Officer of Philips Medical Systems North America. Mr. Curran currently serves on the Board of 3D Systems (NYSE: DDD) and is Chairman of the Audit Committee and a member of the Executive Committee. He was non-executive Chairman and a Director of Resonant Medical before it was sold to Elekta A.B. in 2010.He has previously served as a director for companies in the medical, electronics, and software industries.

 

Arun Menawat has been Novadaq Technologies Inc.’s President and Chief Executive Officer since April 2003. Previously, he held senior management positions at Cedara Software, Tenneco, Inc. and Hercules, Inc. His educational background includes a Bachelor of Science in Biology, University of District of Columbia, Washington, District of Columbia, and a Ph.D. in Chemical Engineering, from the University of Maryland, College Park, MD, and a Fellowship in Biomedical Engineering from the National Institute of Health, Bethesda, MD. He also earned an Executive MBA from the J.L. Kellogg School of Management, Northwestern University, Evanston, Illinois.

 

Peter Albertsen, Chief and Program Director of the Division of Urology, Professor of Surgery, University of Connecticut Health Center

 

Scott Eggener, Co-Director, Prostate Cancer Program Director, Translational and Outcomes Research, Section of Urology, Associate Professor of Surgery, University of Chicago

 

Adam Kibel, Chief of Urology, Brigham and Women's Hospital Chief of Urology, Dana-Farber Cancer Institute, Professor of Surgery,   Harvard Medical School, Dana-Farber/Harvard Cancer Center

 

Eric Klein, Chairman of the Glickman Urological and Kidney Institute, Professor of Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic

Laurence Klotz, Chief of Urology, Sunnybrook Health Sciences Center, Professor of Surgery, University of Toronto

 

Aytekin Oto, Chief of Body MRI, Section Chief of Abdominal Imaging, Professor of Radiology, University of Chicago

 

Clare Tempany-Afdhal, Ferenc Jolesz Chair of Research, Radiology, Brigham and Women's Hospital, Professor of Radiology, Harvard   Medical School

Ian Thompson, Glenda and Gary Woods Distinguished Chair in GU Oncology, Professor, Department of Urology, University of Texas Health Science Center, San Antonio